Plain-English translation of NCT03647358 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new diagnostic imaging test called PET scanning in patients with metastatic thyroid cancer (cancer that has spread). The imaging helps doctors measure how much radioactive iodine your cancer takes up, which is important because it determines whether radioiodine therapy will work well for you.
Currently, doctors use standard methods to decide if radioiodine therapy will benefit patients with thyroid cancer. This new imaging test could give more accurate information before treatment, helping doctors identify patients who will truly benefit from this therapy and spare those who wouldn't from unnecessary treatment.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of a radioactive form of iodine and then undergo up to 4 PET imaging scans over time to measure how much iodine your cancer absorbs and how quickly it clears. Some participants (about 10) may receive an additional small dose of the radioactive tracer and undergo extra scans during any actual radioiodine treatment that follows. The entire process helps your doctors understand whether radioiodine therapy is the right treatment for your specific cancer.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States